Suppr超能文献

与甲硝唑、替硝唑和克林霉素相比,细菌性阴道病(BV)相关细菌对塞克硝唑的敏感性。

Susceptibility of bacterial vaginosis (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin.

作者信息

Petrina Melinda A B, Cosentino Lisa A, Rabe Lorna K, Hillier Sharon L

机构信息

Magee-Womens Research Institute, 204 Craft Avenue, Pittsburgh, PA 15213, USA.

Magee-Womens Research Institute, 204 Craft Avenue, Pittsburgh, PA 15213, USA; University of Pittsburgh, Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital, 300 Halket Street, Pittsburgh, PA 15213, USA.

出版信息

Anaerobe. 2017 Oct;47:115-119. doi: 10.1016/j.anaerobe.2017.05.005. Epub 2017 May 15.

Abstract

Secnidazole, a 5-nitroimidazole with a longer half-life, is structurally related to metronidazole and tinidazole. For treatment of bacterial vaginosis (BV), secnidazole is a suitable single-dose oral drug having a longer serum half-life than metronidazole. The objective of this study was to evaluate the antimicrobial susceptibility of vaginal isolates of facultative and anaerobic bacteria to secnidazole, metronidazole, tinidazole and clindamycin. A total of 605 unique BV-related bacteria and 108 isolates of lactobacilli recovered from the human vagina of US women during the years 2009-2015 were tested for antimicrobial susceptibility by the agar dilution CLSI reference method to determine the minimal inhibitory concentration (MIC). The MIC (μg/mL) for secnidazole was similar to metronidazole and tinidazole for Anaerococcus tetradius (secnidazole: MIC 2; metronidazole: MIC 2; tinidazole: MIC 4), Atopobium vaginae (32; >128; 128), Bacteroides species (2; 2; 2), Finegoldia magna (2; 2; 4), Gardnerella vaginalis (128; 64; 32), Mageeibacillus indolicus (2; 2; 2), Megasphaera-like bacteria (0.5; 0.25; 0.5), Mobiluncus curtisii (128; >128; >128) and Mobiluncus mulieris (>128; >128; >128), Peptoniphilus lacrimalis (4; 4; 4) and Peptoniphilus harei (2; 2; 4), Porphyromonas species (0.25; 0.5; 0.25), Prevotella bivia (8; 8; 8), Prevotella amnii (2; 1; 2) and Prevotella timonensis (2; 2; 2). In this evaluation, 14 (40%) of 35 P. bivia, 5 (14%) of 35 P. amnii and 21 (58%) of 36 P. timonensis isolates were resistant to clindamycin with MIC values of >128 μg/mL. Secnidazole, like metronidazole, was superior to clindamycin for Prevotella spp., Bacteroides spp., Peptoniphilus spp., Anaerococcus tetradius and Finegoldia magna. Clindamycin had greater activity against Atopobium vaginae, Gardnerella vaginalis and Mobiluncus spp. compared to the nitroimidazoles. All 27 Lactobacillus crispatus, 26 (96%) of 27 L. jensenii, 5 (19%) of 27 L. gasseri and 18 (67%) of 27 L. iners isolates were susceptible to clindamycin (MIC ≤2) while the MIC for all lactobacilli tested was >128 μg/mL for secnidazole, metronidazole and tinidazole. Secnidazole has similar in vitro activity against the range of microorganisms associated with BV compared to metronidazole or tinidazole. Further, secnidazole spares lactobacilli, a characteristic which is desirable in drugs used to treat bacterial vaginosis.

摘要

塞克硝唑是一种半衰期较长的5-硝基咪唑类药物,在结构上与甲硝唑和替硝唑相关。对于细菌性阴道病(BV)的治疗,塞克硝唑是一种合适的单剂量口服药物,其血清半衰期比甲硝唑长。本研究的目的是评估兼性厌氧菌和厌氧菌的阴道分离株对塞克硝唑、甲硝唑、替硝唑和克林霉素的抗菌敏感性。通过琼脂稀释CLSI参考方法对2009年至2015年期间从美国女性阴道中分离出的605株独特的BV相关细菌和108株乳酸杆菌进行抗菌敏感性测试,以确定最低抑菌浓度(MIC)。塞克硝唑的MIC(μg/mL)与甲硝唑和替硝唑对以下细菌的MIC相似:四联厌氧球菌(塞克硝唑:MIC 2;甲硝唑:MIC 2;替硝唑:MIC 4)、阴道阿托波菌(32;>128;128)、拟杆菌属(2;2;2)、巨大芬戈尔德菌(2;2;4)、阴道加德纳菌(128;64;32)、产吲哚马吉杆菌(2;2;2)、巨球形菌属样细菌(0.5;0.25;0.5)、柯氏动弯杆菌(128;>128;>I28)和穆氏动弯杆菌(>128;>128;>128)、泪栖胨球菌(4;4;4)和哈氏胨球菌(2;2;4)、卟啉单胞菌属(0.25;0.5;0.25)、二路普雷沃菌(8;8;8)、羊膜普雷沃菌(2;1;2)和蒂莫内斯普雷沃菌(2;2;2)。在本次评估中,35株二路普雷沃菌中的14株(40%)、35株羊膜普雷沃菌中的5株(14%)和36株蒂莫内斯普雷沃菌中的21株(58%)对克林霉素耐药,MIC值>128 μg/mL。与甲硝唑一样,塞克硝唑对普雷沃菌属、拟杆菌属、胨球菌属、四联厌氧球菌和巨大芬戈尔德菌的抗菌活性优于克林霉素。与硝基咪唑类药物相比,克林霉素对阴道阿托波菌、阴道加德纳菌和动弯杆菌属的活性更强。所有27株卷曲乳酸杆菌、27株詹氏乳酸杆菌中的26株(96%)、27株加氏乳酸杆菌中的5株(19%)和27株惰性乳酸杆菌中的18株(67%)对克林霉素敏感(MIC≤2),而所有测试乳酸杆菌对塞克硝唑、甲硝唑和替硝唑的MIC均>128 μg/mL。与甲硝唑或替硝唑相比,塞克硝唑对与BV相关的一系列微生物具有相似的体外活性。此外,塞克硝唑对乳酸杆菌无影响,这是用于治疗细菌性阴道病的药物所期望的特性。

相似文献

3
Antibiotic susceptibility of Atopobium vaginae.阴道阿托波菌的抗生素敏感性
BMC Infect Dis. 2006 Mar 16;6:51. doi: 10.1186/1471-2334-6-51.
8
Bacterial vaginosis, Atopobium vaginae and nifuratel.细菌性阴道病、阴道阿托波菌与硝呋太尔。
Curr Clin Pharmacol. 2012 Feb 1;7(1):36-40. doi: 10.2174/157488412799218824.

引用本文的文献

5
Bacterial vaginosis.细菌性阴道病
Nat Rev Dis Primers. 2025 Jun 19;11(1):43. doi: 10.1038/s41572-025-00626-1.
8
An in silico framework for the rational design of vaginal probiotic therapy.用于阴道益生菌疗法合理设计的计算机模拟框架。
PLoS Comput Biol. 2025 Feb 14;21(2):e1012064. doi: 10.1371/journal.pcbi.1012064. eCollection 2025 Feb.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验